Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-21-012213
Filing Date
2021-05-14
Accepted
2021-05-14 09:47:24
Documents
64
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atos20210331b_10q.htm 10-Q 695988
2 EXHIBIT 31.1 ex_241693.htm EX-31.1 11796
3 EXHIBIT 31.2 ex_241694.htm EX-31.2 12348
4 EXHIBIT 32.1 ex_241695.htm EX-32.1 6348
5 EXHIBIT 32.2 ex_241696.htm EX-32.2 6893
  Complete submission text file 0001437749-21-012213.txt   3649255

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT atos-20210331.xml EX-101.INS 574402
7 XBRL TAXONOMY EXTENSION SCHEMA atos-20210331.xsd EX-101.SCH 48576
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atos-20210331_cal.xml EX-101.CAL 29179
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20210331_def.xml EX-101.DEF 302004
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20210331_lab.xml EX-101.LAB 261720
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20210331_pre.xml EX-101.PRE 327392
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 21922310
SIC: 2834 Pharmaceutical Preparations